Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD73/AXL.HypoSti.CAR-T in Advanced Solid Tumors
NCT06939270Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD73/AXL.HypoSti.CAR-T cells in solid tumor, sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of treatment related adverse events at 12 months, Incidence of dose limiting toxicities at 28 days and 2 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
CD73/AXL.HypoSti.CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06939270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939270.